Abstract
The aim of the present study was to characterize the pattern of adverse drug reactions (ADRs) reported in a university teaching hospital in south-east Serbia. The study was conducted based on ADRs reported during a six-month period to the ADR reporting unit of the university clinical center. Evaluation of data was done for various parameters, such as patient demographics, drug and reaction characteristics, and outcome of reactions. Assessment was also done for causality, severity and predisposing factors. During the 6-month study period, 44 ADRs were reported, with an overall incidence of 0.33%. No significant difference was seen in the overall incidence of ADRs observed in males and females. Incidence of ADRs among elderly (43.2%) and older (25%) adults was significantly higher than in other age groups. Type A reactions (66.7%) accounted for majority of the reports. The most commonly affected organ system was the renal system, (22.7%) with hyperkalemia as the only reported reaction. ACE inhibitors (48.6%) were the drug class most commonly involved, where fosinopril (25.7%) was the individual drug most frequently reported. Additional treatment was pursued for management of ADRs in majority (52.3%) of the reports. In 52.3 % of the reports, the patient had recovered from the reaction by the time of evaluation. Upon causality assessment, the majority of the reports were rated as probable (43.2%). Mild and moderate reactions accounted for 43.2% and 54.6%, respectively. In 36.3% of the reports, the reaction was considered to be preventable. The most common predisposing factors were polypharmacy and multiple disease state. The pattern of ADRs reported in our hospital is comparable to the results of studies conducted in hospital set up elsewhere. Our evaluations revealed opportunities for intervention to ensure safer drug use.
[1] Davies E.C., Green C.F., Mottram D.R., Pirmohamed M., Adverse drug reactions in hospital in-patients: a pilot study, Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 335–341 http://dx.doi.org/10.1111/j.1365-2710.2006.00744.x10.1111/j.1365-2710.2006.00744.xSearch in Google Scholar
[2] Somers A., Petrovic M., Robays H., Bogaert M., Reporting adverse drug reactions on a geriatric ward: a pilot project, Eur J Clin Pharmacol, 2003, 58, 707–714 10.1007/s00228-002-0535-5Search in Google Scholar
[3] Classen D.C., Pestotnik S.L., Evans R.S., Lloyd J.F., Burke J.P., Adverse drug events in hospitalized patients, Excess length of stay, extra costs, and attributable mortality, JAMA, 1997, 277, 301–306 http://dx.doi.org/10.1001/jama.277.4.30110.1001/jama.277.4.301Search in Google Scholar
[4] Lagnaoui R., Moore N., Fach J., Longy-Boursier M., Begaud B., Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability, Eur J Clin Pharmacol, 2000, 56, 181–186 http://dx.doi.org/10.1007/s00228005073810.1007/s002280050738Search in Google Scholar
[5] Dormann H., Muth-Selbach U., Krebs B., Criegee-Rieck M., Tegeder I., Schneider H.T., et al., Incidence and costs of adverse drug reactions during hospital stay, Drug Saf, 2000, 22, 161–168 http://dx.doi.org/10.2165/00002018-200022020-0000710.2165/00002018-200022020-00007Search in Google Scholar
[6] Moore N., Lecointre D., Nobelt C., Mabille M., Frequency and cost of serious adverse drug reactions in a department of general medicine, Br J Clin Pharmacol, 1998, 45, 301–308 http://dx.doi.org/10.1046/j.1365-2125.1998.00667.x10.1046/j.1365-2125.1998.00667.xSearch in Google Scholar
[7] Levy M., Azaz-Livshits T., Sadan B., Shalit M., Geisslinger G., Brune K., Computerized surveillance of adverse drug reactions in hospital: implementation, Eur J Clin Pharmacol, 1999, 54, 887–892 http://dx.doi.org/10.1007/s00228005057110.1007/s002280050571Search in Google Scholar
[8] Ditto A.M., Drug allergy, In, Grammer L.C., Greenberger P.A., editors. Patterson’s allergic diseases. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2002. p.295 Search in Google Scholar
[9] Jick H., Adverse drug reactions: the magnitude of the problem, J Allergy Clin Immunol, 1984, 74, 555–557 http://dx.doi.org/10.1016/0091-6749(84)90106-410.1016/0091-6749(84)90106-4Search in Google Scholar
[10] Lazarou J., Pomeranz B.H., Corey P.N., Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 1998, 279, 1200–1205 http://dx.doi.org/10.1001/jama.279.15.120010.1001/jama.279.15.1200Search in Google Scholar PubMed
[11] Hartwig S.C., Siegel J., Schneider P.J., Preventability and severity assessment in reporting adverse drug reactions, Am J Hosp Pharm, 1992, 49, 2229–2232 10.1093/ajhp/49.9.2229Search in Google Scholar
[12] American Society of Health System Pharmacists, ASHP guidelines on adverse drug reaction monitoring and reporting, Am J Hosp Pharm, 1989, 46, 336–337 10.1093/ajhp/46.2.336Search in Google Scholar
[13] Moride Y., Haramburu F., Requeyo A.A., Begaud B., Underreporting of adverse drug reactions in general practice, Br J Clin Pharmacol, 1997, 43(2), 177–181 http://dx.doi.org/10.1046/j.1365-2125.1997.05417.x10.1046/j.1365-2125.1997.05417.xSearch in Google Scholar
[14] Alvarez-Requejo A., Carvajal A., Begaud B., Moride Y., Vega T., Martin Arias L.H., Underreporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system, Eur J Clin Pharmacol, 1998, 54, 483–488 http://dx.doi.org/10.1007/s00228005049810.1007/s002280050498Search in Google Scholar
[15] Gallelli L., Ferreri M., Colosimo M., Pirritano D., Flocco M.A., Pelaia G., et al., Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy, Pharmacol Res, 2003, 47(6), 493–499 http://dx.doi.org/10.1016/S1043-6618(03)00003-310.1016/S1043-6618(03)00003-3Search in Google Scholar
[16] Rawlins M.D., Thompson J.W., Pathogenesis of adverse drug reactions, In: Davies DM, editor Textbook of adverse drug reactions. 1st ed.Oxford: Oxford University Press; 1977. p.44 Search in Google Scholar
[17] WHO Collaborating Centre for Drug Statistics Methodology. Completed ATC Index 2005 Search in Google Scholar
[18] Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al., A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther, 1981, 30, 239–245 10.1038/clpt.1981.154Search in Google Scholar PubMed
[19] Lau P.M., Stewart K., Dooley M.J., Comment: hospital admissions resulting from preventable adverse drug reactions, Ann Pharmacother 2003, 37, 303–312 http://dx.doi.org/10.1345/aph.1A333a10.1345/aph.1A333aSearch in Google Scholar
[20] Edwards I.R., Pharmacological basis of adverse drug reactions, In: Speight TM, Holford NHG, editors. Avery’s drug treatment. 4th ed. Auckland, New Zealand: Adis International; 1997. p. 261–299 Search in Google Scholar
[21] Parthasarathi G., Olsson S., Adverse Drug Reactions, In: Parthasarathi G., Nyfort-Hansen K., Nahata M.C., editors. A textbook of clinical pharmacy practice-essential concepts and skills 1st ed. place: Orient Longmann; 2005. p. 85–102 Search in Google Scholar
[22] Veehof L.J.G., Stewart R.E., Haaijer-Ruskamp F.M., Meyboom-de Jong B., The development of polypharmacy: A longitudinal study, Family Practice, 2000, 17(3), 261–267 http://dx.doi.org/10.1093/fampra/17.3.26110.1093/fampra/17.3.261Search in Google Scholar PubMed
[23] Bennett B.S., Lipman A.G., Comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions, Am J Hosp Pharm, 1977, 34, 931–936 10.1093/ajhp/34.9.931Search in Google Scholar
[24] Impicciatore P., Choonara I., Clarkson A., Provasi D., Pandolfini C., Bonati M., Incidence of adverse drug reactions in pediatric in/out-patients: a systematic review and meta-analysis of prospective studies, Br J Clin Pharmacol, 2001, 52(1), 77–83 http://dx.doi.org/10.1046/j.0306-5251.2001.01407.x10.1046/j.0306-5251.2001.01407.xSearch in Google Scholar PubMed PubMed Central
[25] Montastruc J.L., Lapeyre-Mestre M., Bagheri H., Fooladi A., Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France, Fundam Clin Pharmacol, 2002, 16(5), 343–346 http://dx.doi.org/10.1046/j.1472-8206.2002.00100.x10.1046/j.1472-8206.2002.00100.xSearch in Google Scholar PubMed
[26] Bates D.W., Cullen D.J., Laird N., Petersen L.A., Small S.D., Servi D., et al., Incidence of adverse drug events and potential adverse drug eventsimplications for prevention, JAMA, 1995, 55(1), 29–34 http://dx.doi.org/10.1001/jama.274.1.2910.1001/jama.274.1.29Search in Google Scholar
[27] Murphy B.M., Frigo LC., Development, implementation and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital. Hosp Pharm, 1993, 28(12), 1199–1204 Search in Google Scholar
[28] Suh D.C., Woodall B.S., Shin S.K., Hermes-De-Santis E.R., Clinical and economic impact of adverse drug reactions in hospitalized patients, Ann Pharmacother, 2000, 34, 1373–1379 10.1345/1542-6270(2000)034<1373:CAEIOA>2.0.CO;2Search in Google Scholar
[29] Prosser T.R., Kamysz P.L., Multidisciplinary adverse drug reaction surveillance program. Am J Hosp Pharm, 1990, 47(6), 1334–1339 10.1093/ajhp/47.6.1334Search in Google Scholar
[30] Acker C.G., Johnson J.P., Palevsky P.M., Greenberg A., Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines, Arch Intern Med, 1998, 158, 917–924 http://dx.doi.org/10.1001/archinte.158.8.91710.1001/archinte.158.8.917Search in Google Scholar
[31] Rimmer J.M., Horn J.F., Gennari F.J., Hyperkalemia as a complication of drug therapy, Arch Intern Med, 1987, 147, 867–869 http://dx.doi.org/10.1001/archinte.147.5.86710.1001/archinte.147.5.867Search in Google Scholar
[32] Perazella M.A., Drug-induced hyperkalemia: old culprits and new offenders, Am J Med, 2000, 109, 307–314 http://dx.doi.org/10.1016/S0002-9343(00)00496-410.1016/S0002-9343(00)00496-4Search in Google Scholar
[33] Ahuja T., Freeman D. Jr., Mahnken J.D., Agraharkar M., Siddiqui M., Memon A., Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors, Am J Nephrol, 2000, 20, 268–272 http://dx.doi.org/10.1159/00001359910.1159/000013599Search in Google Scholar
[34] Reardon L.C., Macpherson D.S., Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors, Arch Intern Med, 1998, 158, 26–32 http://dx.doi.org/10.1001/archinte.158.1.2610.1001/archinte.158.1.26Search in Google Scholar
[35] Gholami K., Shalviri G., Factors associated with preventability, predictability and severity of adverse drug reactions, Ann Pharmacother, 1999, 33(2), 236–240 http://dx.doi.org/10.1345/aph.1744010.1345/aph.17440Search in Google Scholar
[36] Gonzalez-Martin G., Caroca C.M., Paris E., Adverse drug reactions /ADRs/ in hospitalized pediatric patients-a prospective study, Int J Clin Pharmacol Ther, 1998, 36(10), 530–533 Search in Google Scholar
[37] Jose J., Rao P.G.M., Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital, Pharmacological Research, 2006, 54(3), 226–233 http://dx.doi.org/10.1016/j.phrs.2006.05.00310.1016/j.phrs.2006.05.003Search in Google Scholar
[38] Kanjanarat P., Winterstein A.G., Johns T.E., Hatton R.C., Gonzalez-Rothi R., Segal R., Nature of preventable adverse drug events in hospitals: a literature review, Am J Health Syst Pharm, 2003, 60, 1750–1759 10.1093/ajhp/60.17.1750Search in Google Scholar PubMed
[39] Bates D.W., Leape L.L., Petrycki S., Incidence and preventability of adverse drug events in hospitalized adults, J Gen Intern Med, 1993, 8, 289–294 http://dx.doi.org/10.1007/BF0260013810.1007/BF02600138Search in Google Scholar PubMed
[40] Gandhi T.K., Weingart S.N., Borus J., Seger A.C., Peterson J., Burdick E., et al., Adverse drug events in ambulatory care, N Eng J Med, 2003, 348, 1156–1164 http://dx.doi.org/10.1056/NEJMsa02070310.1056/NEJMsa020703Search in Google Scholar PubMed
[41] Evans R.S., Lloyd J.F., Stoddard G.J., Neberker J.R., Samore M.H., Risk factors for adverse drug events: a 10 year analysis, Ann Pharmacother, 2005, 39, 1161–1168 http://dx.doi.org/10.1345/aph.1E64210.1345/aph.1E642Search in Google Scholar PubMed
[42] Fonescue E.B., Kausbal R., Landrigan C.P., McKenna K.J., Clapp M.D., Federico F., et al., Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients, Pediatrics, 2003, 111(4 Pt 1), 722–729 10.1542/peds.111.4.722Search in Google Scholar PubMed
[43] Field T.S., Gurwitz J.H., Avorn J., McCormick D., Jain S., Eckier M., et al., Risk factors for adverse drug events among nursing home residents, Arch Intern Med, 2001, 161, 1629–1634 http://dx.doi.org/10.1001/archinte.161.13.162910.1001/archinte.161.13.1629Search in Google Scholar PubMed
[44] Bates D.W., Miller E.B., Cullen, Burdick L., Williams L., Laird N., et al., Patient risk factors for adverse drug events in hospitalized patients, Arch Intern Med, 1999, 159, 2553–2559 http://dx.doi.org/10.1001/archinte.159.21.255310.1001/archinte.159.21.2553Search in Google Scholar PubMed
© 2010 Versita Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.